| Product Information |
BR-924_PI_01.pdf
|
| Registration Number |
BR-924
|
| Generic Name |
Meningococcal Groups A, C, W-135 and Y Conjugate
Vaccine
|
| Brand Name |
Nimenrix
|
| Dosage Strength |
Formulation: After reconstitution, each dose (0.5 mL) contains: Neisseria meningitidis group A polysaccharide* Neisseria meningitidis group C polysaccharide* Neisseria meningitidis group W-135 polysaccharide* Neisseria meningitidis group Y polysaccharide*
5 mcg 5 mcg 5 mcg 5 mcg
* conjugated to tetanus toxoid carrier protein
44 mcg
|
| Dosage Form |
Lyophilized Powder for Solution for Injection (IM)
|
| Classification |
Prescription Drug (Rx)
|
| Packaging |
Type I clear glass vial + 0.5 mL pre-filled glass syringe
(0.9% Sodium Chloride as diluent) with 2 separate needles (Box of l’s)
|
| Pharmacologic Category |
-
|
| Manufacturer |
Pfizer Manufacturing Belgium NV
|
| Country of Origin |
Belgium
|
| Trader |
|
| Importer |
Pfizer, Inc.
|
| Distributor |
|
| Application Type |
Initial (Variation)
|
| Issuance Date |
03 August 2022
|
| Expiry Date |
03 August 2027
|